Large gap with delayed quotes
|
Last quote
02/28/2026
-
02:00:00
|
Bid
02/27/2026 -
21:59:59
|
Bid Volume |
Ask
02/27/2026 -
21:59:59
|
Ask Volume |
|---|---|---|---|---|
|
35.70
-0.08
(
-0.22% )
|
35.72
|
100 |
35.73
|
3,000 |
Analysis date: 24.02.2026
Global Evaluation
Slightly negative
Slightly negative
The stock is classified in the slightly negative zone since 20.02.2026.
Interest
Very weak
Very weak
One star since 20.02.2026.
Earnings Rev Trend
-0.10
-0.10
Compared to seven weeks ago, the analysts have not significantly revised their earnings per share estimates (changes between +1% and -1% are considered neutral). But the last significant trend is negative since 07.11.2025 at a price of 73.72.
Evaluation
Undervalued
Undervalued
Based on its growth potential and our own criteria, we believe the share price is currently moderately undervalued.
MT Tech Trend
Negative
Negative
The dividend-adjusted forty day technical trend is negative since 31.12.2025.
4wk Rel Perf
-16.68%
-16.68%
The four-week dividend-adjusted underperformance versus SP500 is 16.68%.
Sensibility
High
High
The stock has been on the high-sensitivity level since 29.08.2025.
Bear Market Factor
High
High
On average, the stock has a tendency to amplify the drops in the index by 1.76%.
Bad News Factor
Low
Low
When the stock's pressure is specific, the market sanction on average is 4.10%.
Mkt Cap in $bn
3.84
3.84
With a market capitalization between $2 & $8bn, CORCEPT THERAPEUTICS is considered a mid-cap stock.
G/PE Ratio
27.29
27.29
A ratio (Forecasted Growth + Estimated Dividend Yield/ Estimated Price Earnings) higher than 1.6 often suggests the projected growth is a result of a base effect, meaning the company can often be in a turn around situation. In this case, the estimated PE is a better indicator of a stock's expected growth than the Long Term Growth (LT Growth).
LT P/E
3.61
3.61
The estimated PE is for the year 2029.
LT Growth
98.52%
98.52%
The annualized growth estimate is for the current year to 2029.
Avg. Nb analysts
4
4
Over the last seven weeks, an average of 4 analysts provided earnings per share estimates.
Dividend Yield
0.00%
0.00%
The company is not paying a dividend.
Beta
159
159
For 1% of index variation, the stock varies on average by 1.59%.
Correlation
0.27
0.27
Stock movements are strongly independent of index variations.
Value at Risk
26.92
26.92
The value at risk is estimated at USD 26.92. The risk is therefore 73.80%. This value is based on the historical volatility for a medium time period (1 month) with a confidence of 95%.
First Analysis Date
15.07.2025
15.07.2025